Related Experiment Video
Updated: Aug 7, 2026
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Novel nonsteroidal topical therapies for pediatric atopic dermatitis: a systematic review and network meta-analysis
Yuheng Yang1, Dan Zhao2,3, Yicheng Wang4
1Drug and Equipment Section, Chengdu Children Special Hospital, Chengdu, Sichuan, China.
Background:
Novel nonsteroidal topical therapies are increasingly used for pediatric atopic dermatitis (AD), but their comparative efficacy and safety remain unclear because direct active-comparator evidence is limited.
Methods:
We conducted a systematic review and frequentist network meta-analysis (NMA) of randomized controlled trials (RCTs) evaluating novel nonsteroidal topical therapies in children with AD. The study was registered in PROSPERO (CRD420261400624). Efficacy outcomes included Investigator's Global Assessment treatment success (IGA-TS), Eczema Area and Severity Index 75 response (EASI-75), and EASI-90. Safety outcomes included treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs). Treatment nodes were defined by drug, concentration, and dosing frequency. Pairwise vehicle-controlled meta-analyses, sensitivity analysis, and subgroup analyses by treatment duration and age were also performed.
Results:
Twelve articles reporting 15 RCTs involving 3,994 pediatric patients were included. The network was largely centered on vehicle, with only one active-comparator trial. Most active regimens improved IGA-TS versus vehicle, except tapinarof 0.5% once daily. For EASI-75, five of ten evaluated active regimens showed significant benefit, while all six regimens evaluated for EASI-90 were superior to vehicle. Delgocitinib 0.5% twice daily ranked highest for IGA-TS and EASI-75, whereas difamilast 1% twice daily ranked highest for EASI-90. No consistent increase in TEAEs or TRAEs was observed. Pairwise meta-analyses and sensitivity analysis were generally consistent with the primary findings. Subgroup analyses suggested timepoint- and age-related differences, but stratified evidence was limited.
Conclusion:
Novel nonsteroidal topical therapies provide effective short-term steroid-sparing options for pediatric AD without a clear overall safety penalty. Further head-to-head, long-term, and age-stratified trials are needed.
Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420261400624.
Related Concept Videos
01:27Acne Infection
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion